“Insulin assays have been used for decades, and although they were validated once upon a time, industry guidelines have since been updated, improved and changed. How do these old methods stand against modern needs and requirements?
BioAgilytix (NC, USA) have announced their partnership with Sword Bio (IL, USA), to expand their bioanalytical services to include Sword Bio’s detection platform for immunoassays.
Read time: 3 mins
In this installment, Robert discusses how to get to grips with metabolites; the ways in which metabolites may affect the performance and reliability of an assay, and what could be done to overcome them.
A sensitive method for the quantitation of the peptide-based glucagon-like peptide-1 receptor agonist liraglutide in plasma using microfluidics chromatography tandem MS
In this article, the authors discuss an LC–MS/MS assay for the quantitation of liraglutide, a peptide-based injectable glucagon-like peptide-1 receptor agonist, as a convenient alternative to the enzyme-linked immunosorbent assay.
Issue 23 of Bioanalysis volume 9 is now available, including an editorial discussing the matrix effects, a methodology on assay signaling and a White Paper on the rise of hybrid LBA/LCMS immunogenicity assays.
In this conference report we discuss our highlights from the 10th Open Meeting of the European Bioanalytical Forum – a New Journey begins (Barcelona, Spain; 14–17 November).
Improving the sensitivity and specificity of a bioanalytical assay for the measurement of certolizumab pegol
This article looks at a new electrochemiluminescence immunoassay developed to measure certolizumab pegol levels in human plasma. Learn more in this article from Bioanalysis.
Parallelism experiments to evaluate matrix effects, selectivity and sensitivity in ligand-binding assay method development: pros and cons
This review compares and discusses all available approaches that can be used to assess key assay parameters for pharmacokinetic and biomarker ligand-binding assays. Find out more in this article from Bioanalysis.
Challenges of single and multiplex biomarker validation on ‘planet Earth’ versus ‘planet Biomarkertopia’
Available to view on demand
This presentation focuses on the current status and industry standards for Fit-for-Purpose biomarker assay validations.
A DNA methylation biomarker (POU4F3) and quantitative assay may provide a two-pronged approach to improve the preclinical identification and diagnosis of cervical cancers.